Skip to main content
. 2016 Aug 3;311(4):R676–R688. doi: 10.1152/ajpregu.00237.2016

Fig. 8.

Fig. 8.

Comparison CRH for wild-type (sEH+/+) mice before and after infusion of rosiglitazone (PPARγ-agonist, 10 μM); administration of rosiglitazone increased CRH in both sEH+/+and sEH−/− mice. In sEH+/+ mice, repayment volume (RV) was increased by 37% (A; P = 0.04), repayment/debt ratio (R/D) by 38% (B; P = 0.03), repayment duration (RD) by 38% (C; P = 0.05), and baseline coronary flow (CF) (D; P = 0.0280). In sEH−/− mice, rosiglitazone increased RV by 37% (A; P = 0.04), repayment/debt ratio (R/D) by 23% (B; P = 0.03), RD by 50% (C; P = 0.01), and baseline coronary flow (CF) (D; P = 0.04). Comparing sEH−/− and sEH+/+ mice: RV and R/D were increased more in sEH−/− vs. sEH+/+ mice (P = 0.02 and P = 0.05, respectively). In both sEH+/+ and sEH−/− mice, PHF (E), HR (F), and LVDP (data not shown) were not significantly changed by rosiglitazone. *P ≤ 0.05 vs. sEH+/+. #P ≤ 0.05 vs. sEH−/−. n = 6 sEH+/+, n = 7 sEH−/−.